Two classes of fused nitrogen heterocycles were designed as CK2 inhibitor candidates on the basis of previous structure-activity relationship (SAR) studies. Various dipyrrolo[3,2-b:2',3'-e]pyridine and benzo[g]indazole derivatives were prepared using transition-metal-catalysed cascade and/or multicomponent reactions. Biological evaluation of these candidates revealed that benzo[g]indazole is a promising scaffold for potent CK2 inhibitors. The inhibitory activities on cell proliferation of these potent CK2 inhibitors are also presented.
Introduction
The protein kinase CK2 (previously called casein kinase II) is a ubiquitous and highly pleiotropic serine/threonine kinase for more than 300 protein substrates. A number of reports have suggested that CK2 is a potential target for cancer treatment because CK2 is overexpressed in a wide variety of tumours, 1 and various small-molecule CK2 inhibitors have been developed. 2 CK2 predominantly forms a heterotetramer composed of two catalytic subunits (CK2 and/or CK2') and two regulatory subunits (CK2). 3 The majority of reported small-molecule CK2 inhibitors target the ATP-binding site of the catalytic subunits. A benzonaphthyridine derivative CX-4945 (1) has been reported as a potent ATP-competitive CK2 inhibitor, and is currently undergoing clinical trials for cancer treatment (Figure 1 ). 4 We have also carried out structure-activity relationship (SAR) studies 5 and crystallographic analyses 6 of pyrazine-based CK2 inhibitors 2 5b (Figure 1 ) to obtain structural information for the design of novel CK2 inhibitors. These inhibitors 2 bind to CK2 with a planar horseshoe-shaped conformation to support favourable interactions via van der Waals contacts with hydrophobic residues (Leu45, Val53, Val66, Ile95, Phe113, His160, Met163, and Ile174) in CK2 as well as hydrogen bonds with the surrounding residues. A nitrogen atom at the 4-position of a pyrazine ring interacts with the backbone NH group of Val116 in the hinge region. The carboxyl group, which is necessary for binding to CK2, interacts by a salt bridge and hydrogen bonds with the Lys68 -amino group and the backbone NH group of Asp175 in the activation loop, and a water molecule in the active site.
We recently identified 2-phenyl-1,3,4-thiadiazoles 3 and 3-phenyl-1,2-pyrazole derivatives 4 as CK2 inhibitor led by virtual screening of a compound library (Figure 1 ). 7 Binding mode analysis of the thiadiazole-type inhibitor 3a suggested that unfavourable repulsion exists between one of the thiadiazole nitrogen atoms and the backbone oxygen atom of CK2-Glu114 (Figure 2A ). The pyrazole analogue 4 designed by replacement of the thiadiazole ring in 3b [IC50 = 3.4 M (CK2 and 1.2 M (CK2' with a pyrazole ring would improve the CK2-binding affinity because the NH group of the pyrazole could form an additional hydrogen bond with the Glu114 carbonyl oxygen ( Figure 2B ). The pyrazole-type inhibitor 4 showed more potent inhibitory activity toward CK2 [IC50 = 0.14 M (CK2 and 0.063 M (CK2' than the thiadiazole 3b did. Because the other tautomer, 4', may have unfavourable electrostatic repulsions with the binding region ( Figure 2B ), stabilization of tautomer 4 would enhance the inhibitory activity. In this study, we have designed and synthesized two classes of fused nitrogen heterocycles, using copper-or gold-catalysed cascade reactions. The in vitro inhibitory activities toward two subtypes of the CK2 catalytic subunit (CK2 and CK2') and
anti-proliferative activity of the potent inhibitors are also presented.
Results and discussion

Design
On the basis of our previous SAR studies, we designed two fused nitrogen heterocycles 5 and 6 as novel CK2 inhibitor candidates (Figure 3 ). The highly fused and rigid scaffold would fix the preferred planar conformation and decrease the entropic loss when incorporated into the binding pocket. 6 In the dipyrrolo [3,2-b:2',3' -e]pyridine derivative 5, a nitrogen atom of the pyridine core and a carboxyl group would form favourable electrostatic interactions with CK2, as the pyrazine-based CK2 inhibitors 2 do ( Figure 3A ). 5a,6 The benzo[g]indazole derivatives 6 also have a highly fused and planar structure ( Figure 3B ). More importantly, in the benzo[g]indazole scaffold (a bridged analogue of the phenylpyrazole 4) the desired tautomer of the pyrazole moiety would be preferred because of the fused benzene ring. 8 The stabilization effect of this tautomer in 6 would enhance the chance of the NH group forming favourable interactions with the Glu114 carbonyl oxygen. Preliminary molecular modelling studies of 6a (R 1 = Ph, R 2 = H) using the CK2-3a co-crystal structure suggested that the carboxyl group and two indazole nitrogens could form favourable interactions with CK2 ( Figure 3C ).
Synthesis
We expected that the inhibitor candidates 5 and 6 could be synthesized using the transition-metal-catalysed cascade reactions which have been developed by us in recent years. 9 The synthetic route to dipyrrolo [3,2-b:2',3'-e] pyridine derivatives 5a-e is shown in Scheme 1. The dipyrrolo [3,2-b:2',3'-e] pyridine framework was constructed using copper-catalysed bis-cyclization of 2,6-diethynylpyridine-3,5-diamine 7. 9a The reaction proceeded smoothly to give 1,7-bismesyldipyrrolo [3,2-b:2',3'-e] pyridine (8) . One of the mesyl groups of 8 was selectively removed using Cs2CO3 and methanol to afford 9. The copper-catalysed Ullmann-type coupling of 9 10 with several aryl or heteroaryl carboxylic acid esters, followed by successive deprotection of a mesyl group and an ester, yielded 1-aryldipyrrolo [3,2-b:2',3' -e]pyridines 5a-e. Benzo[g] indazole derivatives 6a-f were prepared via a gold-catalysed three-component annulation and cyclization cascade 9b as a key step (Scheme 2). 4-Amino-3-bromobenzoic acid (12) was converted to the methyl ester 13 under acidic conditions. A Sandmeyer reaction using potassium iodide, followed by a Sonogashira coupling with trimethylsilylacetylene (TMS-acetylene) afforded the common intermediate 15. A second Sonogashira coupling with several acetylenes, using tri-tert-butylphosphine as a ligand for palladium, 11 
Evaluation of CK2 inhibitory activity
The inhibitory activities of the synthesized analogues toward two subtypes of the catalytic subunit of CK2 (CK2 and CK2') are summarised in Table 1 . Although the dipyrrolo[3,2-b:2',3'-e]pyridine derivative bearing a benzoic acid, 5a, had significantly less potent activity, its pyridine congener 5b showed moderate activity toward both CK2 and CK2' (IC50 = 41
M and 26 M, respectively). The position of the carboxyl group also had a distinct effect on the activity: the analogue bearing a 4-carboxypyridine moiety, 5c, exhibited higher activity toward CK2 (IC50 = 14 M) and CK2' (IC50 = 12 M) than did the 3-, 5-, and 2-substituted analogues 5b, 5d, and 5e.
In contrast, benzo[g]indazole derivatives gave more promising results. The 4-methoxybenzene-substituted analogue 6b and the thiophene-substituted one 6d were more potent than the parent pyrazole derivative 4, despite the loss of the amino group on the pyrazole ring of 4, which would form a favourable hydrogen bond with the Val116 carbonyl oxygen ( Figure 2B ). These results suggest that the benzo[g]indazole core would be a more suitable scaffold for potent CK2 inhibitors than the biaryl-type pyrazoles would be, presumably because of the rigidity of the molecule and/or the predominance of the preferable tautomer of the pyrazole ring. The introduction of an isopropyl group as R 2 reduced the binding affinity 100-fold relative to those of the unsubstituted analogues (compare 6b with 6c, and 6d with 6e). On the other hand, the absence of a substituent at the 4-position (R 1 = H, 6g) also lowered the activity relative to those of the other 4-substituted analogues. An aromatic group was preferable to an alkyl chain as the substituent R 1 , and the electrostatic and/or steric environment of the aromatic ring slightly affected the binding affinity. These observations correspond with the predicted binding affinities of -23.8, -22.0, and -20.7 kcal/mol for 6a, 6f, and 6g, respectively.
Evaluation of cytotoxic activity
Compounds 4, 6b, and 6d, which exerted potent CK2 inhibitory activities, were tested for anti-proliferative effects on colorectal cancer cells, HCT-116 ( Figure 4 ). The cancer cells were treated with increasing concentrations of the compounds, and viabilities were measured by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. The pyrazole 4 had a lower than 50% inhibitory effect at 100 M, whereas the benzo[g]indazoles 6b and 6d exhibited moderate inhibitory effects (IC50 = 26.5 M and 21.0 M, respectively), slightly lower than that of 1 (IC50 = 6.7 M). These data are in linear correlation with the CK2 inhibitory effects.
Conclusion
In conclusion, we have designed dipyrrolo[3,2-b:2',3'-e]pyridine and benzo[g]indazole derivatives as novel CK2 inhibitor candidates, based on our previous SAR studies. A series of benzo[g]indazole analogues were efficiently prepared using our three-component cascade reaction.
Evaluation of the resulting derivatives for CK2 inhibitory activities led to identification of novel potent inhibitors such as the thiophene-substituted benzo[g]indazole derivative 6d. Benzo[g]indazole is a promising scaffold for highly potent CK2 inhibitors. These results will provide useful information for further studies on CK2 inhibitors with high selectivity toward the two isozymes CK2 and CK2'.
Experimental section
General
Melting points were measured by a hot stage melting point apparatus (uncorrected). 1 H NMR spectra were recorded using a JEOL AL-400 or JEOL ECA-500 spectrometer, and chemical shifts are reported in  (ppm) relative to TMS as internal standard. 13 C NMR spectra were recorded using a JEOL AL-400 or JEOL ECA-500 spectrometer and referenced to the residual solvent signal. 1 H NMR spectra are tabulated as follows: chemical shift, number of protons, multiplicity (b = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), and coupling constant(s). Exact mass (HRMS) spectra were recorded on a JMS-HX/HX 110A mass spectrometer. Infrared (IR) spectra were obtained on a JASCO FT/IR-4100 FT-IR spectrometer with JASCO ATR PRO410-S.
Compounds 7, 9a 8, 9a and 22 13 were prepared according to the literatures.
1-(Methylsulfonyl)-1,7-dihydrodipyrrolo[3,2-b:2',3'-e]pyridine (9).
To the mixture of 8
(700 mg, 2.23 mmol) in MeOH/THF (1:1, 220 cm 3 ) was added Cs2CO3 (2.18 g, 6.70 mmol). After stirring at rt for 12 h, NH4Cl (835 mg, 15.6 mmol) was added and the mixture was stirred at rt for 1.5
h. It was concentrated in vacuo and the residue was diluted with CHCl3. After filtration, the mixture was concentrated and the residue was chromatographed on silica gel (CHCl3/MeOH = 10/1) to afford the title compound 9 (407 mg, 78%) as a white solid: mp 218-219 °C (decomp); δH (400 MHz; 16.0, 20.1, 30.9, 52.2, 53.3, 55.2, 62.6, 72.4, 113.4 (s, 2H), 124.9, 125.5, 125.7, 125.9, 126.0, 127.6, 127.7, 127.8, 128.5, 129.6, 131.1, 131.2, 131.6 (s, 2H), 133.6, 137.6, 141.3, 157.1, 159.2, and 167.0; HRMS (FAB) 52.3, 55.2, 123.1, 123.5, 125.9, 126.1, 126.3, 126.8, 126.9, 128.0, 128.5, 130.1, 131.1, 132.7, 138.8, 139.5, 152.5, 157.8, and 166.7; HRMS (FAB) 95.0, 98.7, 128.2, 128.4, 129.3, 131.4, 134.1, 154.1, 157.2, and 165.4. Anal. Found: C, 50.3; H, 4.4; N, 4.5. Calc. for C13H14BrN2O3: C, 50.0; H, 4.5; N, 4 .5%.
3-Isopropyl-4-(thiophen-2-yl)-1H-benzo[g]indazole-7-carboxylic acid (6e
Methyl 4-(1-benzyl-1H-pyrazol-5-yl)-3-bromobenzoate (26) . The mixture of 24 (312 mg, 1, 133.8, 133.8, 136.4, 136.5, 138.8, 140.8, and 165 4, 53.9, 80.7, 82.1, 107.9, 122.9, 127.1 (2C), 127.5, 128.5 (2C), 129.5, 130.6, 130.7, 134.4, 137.0, 137.8, 139.0, 140.7, and 165.7; HRMS (FAB) 2, 56.3, 120.2, 122.1, 123.1, 123.6, 125.8, 126.1, 127.2, 128.8, 131.4, 131.5, 132.6, 133.9 (2C), 134.2 (2C), 135.3, 136.6, and 166.9 ; 119.7, 121.4, 122.3, 123.0, 126.6, 129.9, 130.6, 131.1, 132.8, 133.9, and 168 after 30-min incubation in 0.020 cm 3 of Microscinti-0 (PerkinElmer).
Growth inhibition assay
HCT-116 cells were cultured in McCoy's 5A medium (GIBCO), supplemented with 10% (v/v) FBS at 37 °C in a 5% CO2 incubator. Growth inhibition assays using HCT-116 cells were performed in 96-well plates (BD Falcon). HCT-116 cells were seeded at 5000 cells/well in 0.050 cm 3 
